EGFR is dysregulated in several malignant tumors located in head and neck, esophageal, gastric, lung, colorectal, and other organs [6], which correlates with increased metastasis, decreased survival, a poor prognosis [7–10] and radiotherapy (RT) and chemotherapy (CT) resistance[11, 12]. Here, EGFR is linked to cancer.